DOI QR코드

DOI QR Code

Micronutrients and prevention of cervical pre-cancer in HPV vaccinated women: a cross-sectional study

  • Received : 2023.02.01
  • Accepted : 2023.02.18
  • Published : 2023.02.28

Abstract

Objectives: Prophylactic vaccines against high-risk human papillomaviruses (HR-HPVs) hold promise to prevent the development of higher grade cervical intraepithelial neoplasia (CIN 2+) and cervical cancer (CC) that develop due to HR-HPV genotypes that are included in HPV vaccines, but women will continue to develop CIN 2+ and CC due to HR-HPV genotypes that are not included in the quadrivalent HPV vaccine (qHPV) and 9-valent HPV vaccine (9VHPV). Thus, the current vaccines are likely to decrease but not entirely prevent the development of CIN 2+ or CC. The purpose of the study was to determine the prevalence and determinants of CIN 2+ that develop due to HR-HPVs not included in vaccines. Methods: Study population consisted of 1476 women tested for 37 HPVs and known to be negative for qHPVs (6/11/16/18, group A, n = 811) or 9VHPVs (6/11/16/18/31/33/45/52/58, group B, n = 331), but positive for other HR-HPVs. Regression models were used to determine the association between plasma concentrations of micronutrients, socio-demographic, lifestyle factors and risk of CIN 2+ due to HR-HPVs that are not included in vaccines. Results: The prevalence of infections with HPV 31, 33, 35 and 58 that contributed to CIN 2+ differed by race. In group A, African American (AA) women and current smokers were more likely to have CIN 2 (OR = 1.76, P = 0.032 and 1.79, P = 0.016, respectively) while in both groups of A and B, those with higher vitamin B12 were less likely to have similar lesions (OR = 0.62, P = 0.036 and 0.45, P = 0.035, respectively). Conclusions: We identified vitamin B12 status and smoking as independent modifiable factors and ethnicity as a factor that needs attention to reduce the risk of developing CIN 2+ in the post vaccination era. Continuation of tailored screening programs combined with non-vaccine-based approaches are needed to manage the residual risk of developing HPV-related CIN 2+ and CC in vaccinated women.

Keywords

Acknowledgement

Supported by R01 105448 (National Cancer Institute) and T37-MD001448 (Minority Health Research Training grant, National Institute on Minority Health and Health Disparities).

References

  1. HPV Information Centre. Human Papillomavirus and related cancers, Fact sheet 2021 [Internet]. HPV Information Centre; 2021 [cited 2022 Jul 4]. Available from: https://hpvcentre.net/statistics/reports/USA_FS.pdf.
  2. American Cancer Society. Key statistics for cervical cancer [Internet]. American Cancer Society; 2019 [cited 2022 Jul 4]. Available from: https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html.
  3. HPV Information Centre. Statistics [Internet]. HPV Information Centre; 2021 [cited 2022 Jul 4]. Available from: http://www.hpvcentre.net/datastatistics.php.
  4. Center for Disease Control and Prevention. Report to Congress: Prevention of Genital Human Papillomavirus Infection [Internet]. Center for Disease Control and Prevention; 2004 [cited 2022 Jul 25]. Available from: https://www.cdc.gov/std/hpv/2004hpv%20report.pdf.
  5. Centers for Disease Control and Prevention. Genital HPV infection-CDC Fact sheet [Internet]. Centers for Disease Control and Prevention; 2017 [cited 2022 Sep 8]. Available from: https://www.cdc.gov/std/hpv/HPV-FS-July-2017.pdf.
  6. Henk HJ, Insinga RP, Singhal PK, Darkow T. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis 2010; 14(1): 29-36. https://doi.org/10.1097/LGT.0b013e3181ac05e9
  7. Ferreira SE. Cervical intraepithelial neoplasia diagnosis: Emotional impact and nursing implications. Clin Excell Nurse Pract 1998; 2(4):218-224.
  8. McDonald TW, Neutens JJ, Fischer LM, Jessee D. Impact of cervical intraepithelial neoplasia diagnosis and treatment on self-esteem and body image. Gynecol Oncol 1989; 34(3): 345-349. https://doi.org/10.1016/0090-8258(89)90170-4
  9. Rana MM, Huhtala H, Apter D, Eriksson T, Luostarinen T, Natunen K et al. Understanding long-term protection of human papillomavirus vaccination against cervical carcinoma: Cancer registry-based follow-up. Int J Cancer 2013; 132(12): 2833-2838. https://doi.org/10.1002/ijc.27971
  10. Coutlee F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol 2011; 83(6): 1034-1041. https://doi.org/10.1002/jmv.22081
  11. Niccolai LM, Russ C, Julian PJ, Hariri S, Sinard J, Meek JI et al. Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: Associations with race, ethnicity, and poverty. Cancer 2013; 119(16): 3052-3058. https://doi.org/10.1002/cncr.28038
  12. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-527. https://doi.org/10.1056/NEJMoa021641
  13. Badiga S, Chambers MM, Huh W, Eltoum IA, Piyathilake CJ. Expression of p16INK4A in cervical precancerous lesions that is unlikely to be preventable by human papillomavirus vaccines. Cancer 2016; 122(23): 3615-3623. https://doi.org/10.1002/cncr.30229
  14. Piyathilake CJ, Macaluso M, Alvarez RD, Bell WC, Heimburger DC, Partridge EE. Lower risk of cervical intraepithelial neoplasia in women with high plasma folate and sufficient vitamin B12 in the post-folic acid fortification era. Cancer Prev Res (Phila) 2009; 2(7): 658-664. https://doi.org/10.1158/1940-6207.CAPR-08-0175
  15. Brewczynski A, Jablonska B, Kentnowski M, Mrowiec S, Skladowski S, Rutkowski T. The association between carotenoids and head and neck cancer risk. Nutrients 2021; 14(1): 88.
  16. Piyathilake CJ, Macaluso M, Hine RJ, Richards EW, Krumdieck CL. Local and systemic effects of cigarette smoking on folate and vitamin B12. Am J Clin Nutr 1994; 60(4): 559-566. https://doi.org/10.1093/ajcn/60.4.559
  17. Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S et al. Incident cervical HPV infections in young women: Transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011; 20(2): 287-296. https://doi.org/10.1158/1055-9965.EPI-10-0791
  18. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: Implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009; 101(7): 475-487. https://doi.org/10.1093/jnci/djn510
  19. Andersson E, Karrberg C, Radberg T, Blomqvist L, Zetterqvist BM, Ryd W et al. Type-dependent E6/E7 mRNA expression of single and multiple high-risk human papillomavirus infections in cervical neoplasia. J Clin Virol 2012; 54(1): 61-65. https://doi.org/10.1016/j.jcv.2012.01.012
  20. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89(2): 213-228. https://doi.org/10.1016/S0168-1702(02)00190-9
  21. Veldman T, Horikawa I, Barrett JC, Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 2001; 75(9): 4467-4472. https://doi.org/10.1128/JVI.75.9.4467-4472.2001
  22. Zhang Y, Sturgis EM, Dahlstrom KR, Wen J, Liu H, Wei Q et al. Telomere length in peripheral blood lymphocytes contributes to the development of HPV-associated oropharyngeal carcinoma. Cancer Res 2013; 73(19): 5996-6003. https://doi.org/10.1158/0008-5472.CAN-13-0881
  23. Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine 2015; 33(13): 1608-1613. https://doi.org/10.1016/j.vaccine.2015.01.084
  24. Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis. 2015; 137(8): 1931-1937. https://doi.org/10.1002/ijc.29508
  25. Baldur-Felskov B, Dehlendorff C, Junge J, Munk C, Kjaer SK. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014; 25(7): 915-922. https://doi.org/10.1007/s10552-014-0392-4
  26. Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev 2014; 23(10): 1997-2008. https://doi.org/10.1158/1055-9965.EPI-14-0410
  27. Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: A randomized, double-blind trial. Lancet 2017; 390(10108): 2143-2159. https://doi.org/10.1016/S0140-6736(17)31821-4
  28. Piyathilake CJ, Macaluso M, Brill I, Partridge EE, Heimburger DC. Lower red blood cell folate enhances the HPV 16-associated risk of cervical intraepithelial neoplasia. Nutrition 2007; 23(3): 203- 210. https://doi.org/10.1016/j.nut.2006.12.002
  29. Piyathilake CJ, Badiga S, Paul P, Vijayaraghavan K, Vedantham H, Sudula M et al. Indian women with higher serum concentrations of folate and vitamin B12 are significantly less likely to be infected with carcinogenic or high-risk (HR) types of human papillomaviruses (HPVs). Int J Womens Health 2010; 2: 7-12. https://doi.org/10.2147/IJWH.S6522
  30. Duthie SJ, Hawdon A. DNA instability (strand breakage, uracil misincorporation, and defective repair) is increased by folic acid depletion in human lymphocytes in vitro. FASEB J 1998; 12(14): 1491-1497. https://doi.org/10.1096/fasebj.12.14.1491
  31. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc Natl Acad Sci 1997; 94(7): 3290- 3295. https://doi.org/10.1073/pnas.94.7.3290
  32. Fenech M. Micronutrients and genomic stability: A new paradigm for recommended dietary allowances (RDAs). Food Chem Toxicol 2002; 40(8): 1113-1117. https://doi.org/10.1016/S0278-6915(02)00028-5
  33. Duthie SJ, Narayanan S, Blum S, Pirie L, Brand GM. Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr Cancer 2000; 37(2): 245-251. https://doi.org/10.1207/S15327914NC372_18
  34. Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI, Glover TW. FRA3B extends over a broad region and contains a spontaneous HPV 16 integration site: Direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 1996; 5(2): 187-195. https://doi.org/10.1093/hmg/5.2.187
  35. Piyathilake CJ, Macaluso M, Chambers MM, Badiga S, Siddiqui NR, Bell WC et al. Folate and vitamin B12 may play a critical role in lowering the HPV 16 methylation-associated risk of developing higher grades of CIN. Cancer Prev Res (Phila) 2014; 7(11): 1128-1137. https://doi.org/10.1158/1940-6207.CAPR-14-0143
  36. Chaturvedi AK. Beyond cervical cancer: Burden of other HPV-related cancers among men and women. J Adolesc Health 2010; 46(4): S20-S26. https://doi.org/10.1016/j.jadohealth.2010.01.016
  37. Petrosky E, Bocchini Jr. JA, Hariri S, Chesson H, Curtis CR, Saraiya M et al. Use of 9-valent human papillomavirus (HPV) vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64 (11): 300-304.
  38. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J et al. Human papillomavirus vaccination: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(5): 1-30.
  39. Centers for Disease Control and Prevention. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV [Internet]. Centers for Disease Control and Prevention; 2016 [cited 2022 Sep 1]. Available from: https://www.cdc.gov/hpv/downloads/9vhpv-guidance.pdf.
  40. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the advisory committee on immunization practices. Am J Transplant 2017; 17(3): 834-837. https://doi.org/10.1111/ajt.14206